Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

1.

Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IV.

Vincenzi B, Frezza AM, Schiavon G, Spoto C, Silvestris N, Addeo R, Catalano V, Graziano F, Santini D, Tonini G.

Support Care Cancer. 2013 May;21(5):1313-9. doi: 10.1007/s00520-012-1667-5. Epub 2012 Nov 30. Erratum in: Support Care Cancer. 2013 Apr;21(4):1209. Silvestris, Nicola [added].

PMID:
23196819
[PubMed - indexed for MEDLINE]
2.

Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.

Argyriou AA, Velasco R, Briani C, Cavaletti G, Bruna J, Alberti P, Cacciavillani M, Lonardi S, Santos C, Cortinovis D, Cazzaniga M, Kalofonos HP.

Ann Oncol. 2012 Dec;23(12):3116-22. doi: 10.1093/annonc/mds208. Epub 2012 Aug 2.

PMID:
22865779
[PubMed - indexed for MEDLINE]
Free Article
3.

Predicting acute and persistent neuropathy associated with oxaliplatin.

Alejandro LM, Behrendt CE, Chen K, Openshaw H, Shibata S.

Am J Clin Oncol. 2013 Aug;36(4):331-7. doi: 10.1097/COC.0b013e318246b50d.

PMID:
22547012
[PubMed - indexed for MEDLINE]
4.

Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.

Nagashima M, Ooshiro M, Moriyama A, Sugishita Y, Kadoya K, Sato A, Kitahara T, Takagi R, Urita T, Yoshida Y, Tanaka H, Oshiro T, Okazumi S, Katoh R.

Support Care Cancer. 2014 Jun;22(6):1579-84. doi: 10.1007/s00520-014-2132-4. Epub 2014 Jan 24.

PMID:
24452412
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.

Nishioka M, Shimada M, Kurita N, Iwata T, Morimoto S, Yoshikawa K, Higashijima J, Miyatani T, Kono T.

Int J Clin Oncol. 2011 Aug;16(4):322-7. doi: 10.1007/s10147-010-0183-1. Epub 2011 Jan 22.

PMID:
21258836
[PubMed - indexed for MEDLINE]
6.

Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.

Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L.

Anticancer Drugs. 2009 Jun;20(5):396-402. doi: 10.1097/CAD.0b013e32832a2dc1.

PMID:
19287306
[PubMed - indexed for MEDLINE]
7.

Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.

Maindrault-Goebel F, Tournigand C, André T, Carola E, Mabro M, Artru P, Louvet C, de Gramont A.

Ann Oncol. 2004 Aug;15(8):1210-4.

PMID:
15277260
[PubMed - indexed for MEDLINE]
Free Article
8.

Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).

Maindrault-Goebel F, de Gramont A, Louvet C, André T, Carola E, Gilles V, Lotz JP, Tournigand C, Mabro M, Molitor JL, Artru P, Izrael V, Krulik M.

Ann Oncol. 2000 Nov;11(11):1477-83.

PMID:
11142489
[PubMed - indexed for MEDLINE]
Free Article
9.

[Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].

Muto O, Ando H, Ono T, Itagaki H, Kobayashi Y, Onuki M, Akashi T, Tanaka Y, Hanaoka T.

Gan To Kagaku Ryoho. 2007 Apr;34(4):579-81. Japanese.

PMID:
17431344
[PubMed - indexed for MEDLINE]
10.

The effect of monosialotetrahexosylganglioside (GM1) in prevention of oxaliplatin induced neurotoxicity: a retrospective study.

Chen XF, Wang R, Yin YM, Røe OD, Li J, Zhu LJ, Guo RH, Wu T, Shu YQ.

Biomed Pharmacother. 2012 Jun;66(4):279-84. doi: 10.1016/j.biopha.2012.01.002. Epub 2012 Feb 17.

PMID:
22397758
[PubMed - indexed for MEDLINE]
11.

Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.

Tatsushima Y, Egashira N, Narishige Y, Fukui S, Kawashiri T, Yamauchi Y, Oishi R.

Biomed Pharmacother. 2013 Feb;67(1):39-42. doi: 10.1016/j.biopha.2012.10.006. Epub 2012 Nov 15.

PMID:
23206755
[PubMed - indexed for MEDLINE]
12.

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.

Kono T, Hata T, Morita S, Munemoto Y, Matsui T, Kojima H, Takemoto H, Fukunaga M, Nagata N, Shimada M, Sakamoto J, Mishima H.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1283-90.

PMID:
24121454
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

[Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].

Yoshida Y, Hasegawa J, Nishimura J, Hirota M, Kim Y, Nezu R.

Gan To Kagaku Ryoho. 2011 Aug;38(8):1293-6. Japanese.

PMID:
21829066
[PubMed - indexed for MEDLINE]
14.

Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.

Argyriou AA, Cavaletti G, Antonacopoulou A, Genazzani AA, Briani C, Bruna J, Terrazzino S, Velasco R, Alberti P, Campagnolo M, Lonardi S, Cortinovis D, Cazzaniga M, Santos C, Psaromyalou A, Angelopoulou A, Kalofonos HP.

Cancer. 2013 Oct 1;119(19):3570-7. doi: 10.1002/cncr.28234. Epub 2013 Jul 2.

PMID:
23821303
[PubMed - indexed for MEDLINE]
15.

A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.

Lubner SJ, Loconte NK, Holen KD, Schelman W, Thomas JP, Jumonville A, Eickhoff JC, Seo S, Mulkerin DL.

Clin Colorectal Cancer. 2010 Jul;9(3):157-61. doi: 10.3816/CCC.2010.n.021.

PMID:
20643620
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.

Seki K, Senzaki K, Tsuduki Y, Ioroi T, Fujii M, Yamauchi H, Shiraishi Y, Nakata I, Nishiguchi K, Matsubayashi T, Takakubo Y, Okamura N, Yamamori M, Tamura T, Sakaeda T.

Int J Med Sci. 2011 Mar 10;8(3):210-5.

PMID:
21448307
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer.

Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ.

J Clin Oncol. 2006 Sep 1;24(25):4085-91. Erratum in: J Clin Oncol. 2008 Jun 10;26(17):2925-6.

PMID:
16943526
[PubMed - indexed for MEDLINE]
18.

OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.

Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A.

J Clin Oncol. 2006 Jan 20;24(3):394-400.

PMID:
16421419
[PubMed - indexed for MEDLINE]
19.

FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer.

Petrioli R, Paolelli L, Marsili S, Civitelli S, Francini E, Cioppa T, Roviello F, Nettuno R, Intrivici C, Tanzini G, Lorenzi M, Francini G.

Oncology. 2006;70(5):345-50. Epub 2006 Dec 15.

PMID:
17179728
[PubMed - indexed for MEDLINE]
20.

Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.

Uncu D, Aksoy S, Çetin B, Yetişyiğit T, Özdemir N, Berk V, Dane F, Inal A, Harputluoğlu H, Budakoğlu B, Koca D, Sevinç A, Cihan S, Durnalı AG, Özkan M, Öztürk MA, Işıkdoğan A, Büyükberber S, Benekli M, Köş T, Alkış N, Karaca H, Turhal NS, Zengin N; Anatolian Society of Medical Oncology.

Oncology. 2013;84(4):240-5. doi: 10.1159/000336902. Epub 2013 Feb 7.

PMID:
23392240
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk